Assessing the contribution of inflammation in models of Alzheimer's disease.

Inflammation has long been proposed as having a role in AD (Alzheimer's disease), although it remains unclear whether inflammation represents a cause or consequence of AD. Evidence from the clinical setting in support of a role for inflammation in AD includes increased expression of inflammatory mediators and microglial activation in the post-mortem AD brain. Also, epidemiological studies on AD patients under long-term treatment with non-steroidal anti-inflammatory drugs suggest some benefits, although recent prospective trials showed no effect. Furthermore, in AD patients, infection and other systemic inflammatory events worsen symptoms. Finally, several inflammatory genes are associated with increased risk of AD. Therefore, to elucidate the underlying mechanisms of AD and the role of inflammation, researchers have turned to experimental models and here we present a short overview of some key findings from these studies. Activation of microglia is seen in various transgenic models of AD, with both a protective role and a detrimental role being ascribed to it. Early microglial activation is probably beneficial in AD, through phagocytosis of amyloid β-peptide. At later stages however, pro-inflammatory cytokine release from microglia could contribute to neuronal demise. A better understanding of microglial phenotype at the various stages of AD is therefore still required. Although most studies suggest a detrimental role for pro-inflammatory cytokines such as interleukin-1 and tumour necrosis factor in AD, contradictory findings do exist. Age-related and differential cellular expression of these inflammatory mediators is probably a key determinant of their exact contribution to AD. In conclusion, there is no doubt that inflammatory processes are part of the pathophysiology of AD, but a better understanding of the exact contribution at different stages of the disease process is still required before appropriate treatment strategies can be devised.

[1]  D. Mann,et al.  Pathological relationships between microglial cell activity and tau and amyloid β protein in patients with Alzheimer's disease , 2002, Neuroscience Letters.

[2]  S. Hickman,et al.  Microglial Dysfunction and Defective β-Amyloid Clearance Pathways in Aging Alzheimer's Disease Mice , 2008, The Journal of Neuroscience.

[3]  R. Ransohoff,et al.  The many roles of chemokines and chemokine receptors in inflammation. , 2006, The New England journal of medicine.

[4]  L. V. Van Eldik,et al.  Interleukin 1 receptor antagonist knockout mice show enhanced microglial activation and neuronal damage induced by intracerebroventricular infusion of human β-amyloid , 2005, Journal of Neuroinflammation.

[5]  N. Rothwell,et al.  Inflammation in central nervous system injury. , 2003, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[6]  D. Morgan,et al.  Time-dependent reduction in Aβ levels after intracranial LPS administration in APP transgenic mice , 2004, Experimental Neurology.

[7]  N. Zilka,et al.  Genetic background modifies neurodegeneration and neuroinflammation driven by misfolded human tau protein in rat model of tauopathy: implication for immunomodulatory approach to Alzheimer's disease , 2010, Journal of Neuroinflammation.

[8]  J. Relton,et al.  Powerful beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition and cognitive impairment in Alzheimer's disease. , 2008, Brain : a journal of neurology.

[9]  N. Robakis,et al.  It May Take Inflammation, Phosphorylation and Ubiquitination to ‘Tangle’ in Alzheimer’s Disease , 2007, Neurodegenerative Diseases.

[10]  P. Zandi,et al.  Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. , 2010, CNS & neurological disorders drug targets.

[11]  Henrik Zetterberg,et al.  Plasma Aβ in Alzheimer's disease—up or down? , 2006, The Lancet Neurology.

[12]  M. Szyf,et al.  A novel transgenic rat model with a full Alzheimer's-like amyloid pathology displays pre-plaque intracellular amyloid-beta-associated cognitive impairment. , 2010, Journal of Alzheimer's disease : JAD.

[13]  V. Perry,et al.  Systemic inflammation and disease progression in Alzheimer disease , 2009, Neurology.

[14]  D. Wilcock,et al.  Dynamic Complexity of the Microglial Activation Response in Transgenic Models of Amyloid Deposition: Implications for Alzheimer Therapeutics , 2005, Journal of neuropathology and experimental neurology.

[15]  Ying-Dong Zhang,et al.  Anti-TNF-α reduces amyloid plaques and tau phosphorylation and induces CD11c-positive dendritic-like cell in the APP/PS1 transgenic mouse brains , 2011, Brain Research.

[16]  D. Brooks,et al.  Inflammatory risk factors and pathologies associated with Alzheimer's disease. , 2011, Current Alzheimer Research.

[17]  H. Kettenmann,et al.  Microglia: active sensor and versatile effector cells in the normal and pathologic brain , 2007, Nature Neuroscience.

[18]  Inbal Goshen,et al.  Immune modulation of learning, memory, neural plasticity and neurogenesis , 2011, Brain, Behavior, and Immunity.

[19]  K. Zahs,et al.  ‘Too much good news’ – are Alzheimer mouse models trying to tell us how to prevent, not cure, Alzheimer's disease? , 2010, Trends in Neurosciences.

[20]  D. Morgan,et al.  LPS- induced inflammation exacerbates phospho-tau pathology in rTg4510 mice , 2010, Journal of Neuroinflammation.

[21]  Roger N Gunn,et al.  In-vivo measurement of activated microglia in dementia , 2001, The Lancet.

[22]  J. Götz,et al.  Animal models for Alzheimer's disease and frontotemporal dementia: a perspective , 2009, ASN neuro.

[23]  R. Mrak,et al.  Interleukin‐1 in the genesis and progression of and risk for development of neuronal degeneration in Alzheimer’s disease , 2002, Journal of leukocyte biology.

[24]  Jae Woong Lee,et al.  Journal of Neuroinflammation Neuro-inflammation Induced by Lipopolysaccharide Causes Cognitive Impairment through Enhancement of Beta-amyloid Generation , 2022 .

[25]  C. Heyser,et al.  Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin 6 in the brain. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[26]  M. O’Banion,et al.  The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective , 2008, Journal of Neuroinflammation.

[27]  D. Dickson,et al.  Massive gliosis induced by interleukin‐6 suppresses Aβ deposition in vivo: evidence against inflammation as a driving force for amyloid deposition , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[28]  Seth Love,et al.  Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.

[29]  Michael J Owen,et al.  Alzheimer's disease genetics: current knowledge and future challenges , 2011, International journal of geriatric psychiatry.

[30]  Michal Schwartz,et al.  Selective ablation of bone marrow‐derived dendritic cells increases amyloid plaques in a mouse Alzheimer's disease model , 2007, The European journal of neuroscience.

[31]  S. Lockett,et al.  Activation of Toll-like Receptor 2 on Microglia Promotes Cell Uptake of Alzheimer Disease-associated Amyloid β Peptide* , 2006, Journal of Biological Chemistry.

[32]  M. Fornerod,et al.  Characterization of the Drosophila melanogaster genome at the nuclear lamina , 2006, Nature Genetics.

[33]  D. Dickson,et al.  IFN-γ Promotes Complement Expression and Attenuates Amyloid Plaque Deposition in Amyloid β Precursor Protein Transgenic Mice , 2010, The Journal of Immunology.

[34]  M. O’Banion,et al.  Sustained hippocampal IL-1 beta overexpression mediates chronic neuroinflammation and ameliorates Alzheimer plaque pathology. , 2007, The Journal of clinical investigation.

[35]  F. LaFerla,et al.  Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. , 2008, The American journal of pathology.

[36]  S. Rivest,et al.  Neuroprotective properties of the innate immune system and bone marrow stem cells in Alzheimer's disease , 2006, Molecular Psychiatry.

[37]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[38]  James L. Buescher,et al.  Interferon-and Tumor Necrosis Factor-Regulate Amyloid-Plaque Deposition and-Secretase Expression in Swedish Mutant APP Transgenic Mice , 2007 .

[39]  J. Julien,et al.  Bone Marrow-Derived Microglia Play a Critical Role in Restricting Senile Plaque Formation in Alzheimer's Disease , 2006, Neuron.

[40]  H. Braak,et al.  Dystrophic (senescent) rather than activated microglial cells are associated with tau pathology and likely precede neurodegeneration in Alzheimer’s disease , 2009, Acta Neuropathologica.

[41]  S. C.A.,et al.  Non-steroidal anti-inflammatory drugs and Alzheimer's disease: the epidemiological evidence. , 2010 .

[42]  N. Rothwell,et al.  Interleukin-1 and neuronal injury , 2005, Nature Reviews Immunology.

[43]  M. Tansey,et al.  Molecular Neurodegeneration BioMed Central Review , 2009 .

[44]  Tony Wyss-Coray,et al.  Inflammation in Alzheimer disease: driving force, bystander or beneficial response? , 2006, Nature Medicine.

[45]  R. Ransohoff,et al.  Regulation of Tau Pathology by the Microglial Fractalkine Receptor , 2010, Neuron.

[46]  Colm Cunningham,et al.  Systemic infections and inflammation affect chronic neurodegeneration , 2007, Nature Reviews Immunology.

[47]  Tetsuya Suhara,et al.  Longitudinal, Quantitative Assessment of Amyloid, Neuroinflammation, and Anti-Amyloid Treatment in a Living Mouse Model of Alzheimer's Disease Enabled by Positron Emission Tomography , 2007, The Journal of Neuroscience.

[48]  R. Ransohoff,et al.  CX3CR1 deficiency alters microglial activation and reduces beta-amyloid deposition in two Alzheimer's disease mouse models. , 2010, The American journal of pathology.

[49]  M. O’Banion,et al.  Neuroinflammatory processes in Alzheimer’s disease , 2010, Journal of Neural Transmission.

[50]  F. LaFerla,et al.  Lipopolysaccharide-Induced Inflammation Exacerbates Tau Pathology by a Cyclin-Dependent Kinase 5-Mediated Pathway in a Transgenic Model of Alzheimer's Disease , 2005, The Journal of Neuroscience.